Changes planned for Pharmaceutical Water in the Chinese Pharmacopoeia

Recommendation
16-18 September 2025
Barcelona, Spain
Organisation of a GMP-compliant Site Change
The Chinese Pharmacopoeia Committee (CPC) intends to revise monograph 0261 Pharmaceutical Water, as well as the conductivity measurement (0681). In order to ensure the scientific validity and applicability of the changes, the proposed revised text is now being published to solicit professional feedback. The comment period will run until 24 July 2024, and although these are still proposals, it can be assumed that they will be adopted in their current form, presumably by the end of the year.
The planned changes include
- The authorisation of alternative methods for the production of WFI - that's the big news. However, purified water must still be used as feed water for the production of WFI. This is also the current requirement
- Abolition of chemical tests, as these are covered by the conductivity measurement
- Updating the conductivity method, which now corresponds to the USP method. The limit values for WFI correspond to both the USP and the European Pharmacopoeia. The limits for Purified Water are analogue to the higher EP limits compared to the USP
- A conductivity method for sterilised WFI has also been added, with limits analogous to USP & EP
- Greater emphasis on online testing methods
The planned changes are to be welcomed, as they represent further harmonisation between the various global pharmacopoeias.
Related GMP News
25.06.2025Deficiencies in the Water System: Warning Letter to US Manufacturers of OTC Products
11.06.2025Warning Letter to Chinese Manufacturer due to serious Sterility and Hygiene Deficiencies
04.06.2025FAQs regarding Cross Contamination
04.06.2025GMP Deficiencies at French Sterile Manufacturer
14.05.2025Process Validation and Pharmaceutical Water Deficiencies at a US Manufacturer
07.05.2025Another FDA Warning Letter for Indian API manufacturer